Verified
After about a month, I was turning more easily in bed and walking with less hesitation. The improvement was gradual, so I nearly dismissed it during the first two weeks. I still needed physiotherapy for balance.
4 Oct 2026
Azilect
Quality products
24/7 Support
Fast delivery
Delivery
from 4 days
Active ingredient
Rasagiline
Azilect is a prescription medicine for adults with Parkinson’s disease. It contains rasagiline, which selectively inhibits MAO-B to reduce dopamine breakdown and support movement control.
Description
Azilect is a prescription tablet containing rasagiline for adults with Parkinson’s disease. It may be used alone in earlier disease or alongside levodopa and other antiparkinsonian treatment. Rasagiline selectively inhibits MAO-B, helping reduce dopamine breakdown in the brain.
Composition
Azilect contains rasagiline, a selective monoamine-oxidase-B inhibitor, in prescription tablets for adults with Parkinson’s disease. It may be used alone or with levodopa and other antiparkinsonian treatment.
Dosage and usage
Azilect is taken orally once daily, at the dose selected by the prescribing neurologist. The same daily schedule is used whether it forms the main antiparkinsonian treatment or accompanies levodopa.
- Swallow the tablet with water.
- Take it at approximately the same time each day.
- Follow the prescribed regimen without adding extra doses.
- Continue the treatment for the duration directed by the neurologist.
- If a dose is missed, take the next scheduled dose rather than doubling it.
Azilect can be taken with or without food. A very high-fat meal may alter the speed of absorption, so keeping meals and dosing reasonably consistent can make the routine easier to interpret.
The treatment plan may change when levodopa-related dyskinesia, wearing-off, dizziness, hallucinations, or excessive sleepiness develops. Do not stop long-term treatment suddenly without a planned medical review.
Do not take two tablets to compensate for a missed dose. Extra rasagiline does not reliably restore symptom control and may increase adverse effects.
One practical detail is easy to miss: Parkinson’s symptoms can be affected by sleep, infection, dehydration, constipation, and changes in levodopa timing. A short symptom diary can help the neurologist distinguish a medication problem from a temporary physical trigger.
How it works
Monoamine oxidase type B, or MAO-B, is an enzyme that breaks down dopamine in the central nervous system.
Rasagiline binds irreversibly to MAO-B. This reduces enzymatic dopamine breakdown and allows available dopamine to remain active for longer between nerve cells. The effect is not the same as supplying dopamine directly.
Inhibition of Monoamine Oxidase Type B
The mechanism can be understood in three steps:
- Dopamine carries movement-related signals between nerve cells.
- MAO-B breaks down part of the dopamine available in the brain.
- Rasagiline inhibits MAO-B, reducing this breakdown and supporting dopaminergic signalling.
The treatment effect depends on the dopamine-producing nerve pathways that remain active. This explains why rasagiline can improve symptoms without replacing levodopa in advanced disease.
Azilect’s pharmacological action also explains several safety restrictions. Medicines that increase serotonin, stimulate dopamine pathways, or inhibit monoamine oxidase can create excessive neurotransmitter activity when combined inappropriately.
Indications
Azilect is used to manage motor symptoms of Parkinson’s disease, including slowness of movement, stiffness, and difficulty initiating movement. Parkinson’s disease involves the progressive loss of dopamine-producing nerve cells in the brain, so treatment aims to improve dopamine signalling and daily mobility.
The European Medicines Agency recognises Azilect for adult Parkinson’s disease as monotherapy or as add-on treatment with levodopa, with or without other dopaminergic medicines [1]. It does not cure Parkinson’s disease or reverse nerve-cell loss. Its role is symptom control within an individual neurological treatment plan.
Monotherapy and Adjunct Therapy Applications
As monotherapy, Azilect may be prescribed when Parkinson’s symptoms are present but levodopa is not yet part of the treatment plan. As adjunct therapy, it is taken with levodopa when symptom control fluctuates or movement difficulties persist.
Patients respond differently. Some notice smoother movement, while others experience modest changes that become clearer after several weeks. Azilect is not designed to provide an immediate “rescue” effect during a sudden off episode.
Azilect is taken by mouth at a regular time each day. Keeping the dose linked to a routine activity, such as breakfast, can reduce missed doses.
Parkinson’s symptoms can vary from morning to evening. A neurologist may adjust the wider treatment plan if stiffness, tremor, involuntary movements, sleepiness, or falls increase.
Comparison
Different Parkinson’s treatments act at different points in the dopamine pathway. The choice depends on age, symptom pattern, cognitive status, daytime alertness, dyskinesia risk, and the response to existing therapy.
| Treatment approach | Main mechanism | Common clinical role |
|---|---|---|
| Rasagiline | MAO-B inhibition and reduced dopamine breakdown | Early monotherapy or add-on treatment |
| Levodopa | Precursor converted into dopamine in the brain | Strong motor symptom relief, often used as disease progresses |
| Dopamine agonist | Direct stimulation of dopamine receptors | Selected patients needing dopaminergic support |
Levodopa often produces stronger improvement in movement but may contribute to wearing-off and dyskinesia after prolonged treatment. Dopamine agonists can cause sleepiness, hallucinations, swelling, or impulse-control problems in susceptible patients.
Rasagiline may suit a plan that seeks a simpler dopamine-preserving approach. Its symptom benefit can be more modest than levodopa’s, and it still requires interaction screening.
Contraindications
Azilect is not suitable for every person with Parkinson’s disease. It should not be used with certain medicines that can cause dangerous monoamine or serotonin excess.
Fluoxetine and fluvoxamine require special washout planning before or after rasagiline. Other antidepressants, including selective serotonin reuptake inhibitors and tricyclic antidepressants, also require a deliberate prescribing decision rather than casual combination.
Serotonin toxicity can involve agitation, sweating, fever, diarrhoea, muscle stiffness, tremor, and rapid changes in blood pressure or heart rate. Seek urgent medical attention if several of these symptoms appear together after a medication change.
Dopamine agonists, levodopa, and amantadine may be combined with rasagiline in selected patients, yet the total dopaminergic effect can increase hallucinations, sleepiness, low blood pressure, and dyskinesia. Antipsychotic medicines may reduce the benefit of dopaminergic treatment and require specialist selection.
When this is not for you
This Medication Is Not for You If
Azilect is generally unsuitable if you:
- Have a known allergy to rasagiline or an ingredient in the tablet.
- Are taking another MAO inhibitor, including some medicines used for depression or other neurological conditions.
- Use meperidine, tramadol, methadone, or similar opioid medicines.
- Use dextromethorphan for cough unless the prescriber has specifically reviewed the combination.
- Have severe liver impairment.
- Have previously developed a serious reaction to rasagiline.
- Are pregnant or breastfeeding without a specialist assessment of the potential benefit and risk.
Side effects
The most frequently reported adverse effects of rasagiline include headache, dizziness, joint pain, indigestion, nausea, and flu-like symptoms. Some patients experience sleepiness or a fall in blood pressure when standing.
Headache or migraine-like discomfort may occur, although severe or unusual headache deserves assessment. Skin irritation or rash can reflect sensitivity and should be reported if it spreads, blisters, or affects the mouth or eyes.
People taking Azilect with levodopa may experience dyskinesia more often because the combined regimen increases dopaminergic activity. Dyskinesia can look like twisting, writhing, jerking, or uncontrolled movements. Reducing or redistributing levodopa may help, but only the prescriber should make that change.
Possible warning symptoms include:
- Fainting or repeated near-fainting.
- New hallucinations, severe confusion, or marked agitation.
- Sudden inability to stay awake during ordinary activities.
- Facial swelling, breathing difficulty, or a widespread blistering rash.
- Unusual bruising or bleeding, especially with anticoagulants or antiplatelet medicines.
- Severe involuntary movements that interfere with walking or eating.
Clinical safety data describe dizziness, headache, orthostatic hypotension, dyskinesia, hallucinations, and impulse-control symptoms among events requiring attention [2].
Stand up slowly during the first weeks or after a treatment change. If dizziness appears, sit or lie down promptly rather than trying to walk through it.
A patient may not connect daytime sleep attacks with Parkinson’s treatment. Sudden sleep episodes are clinically relevant, especially before driving or operating machinery.
Common mistakes
Poor outcomes can result from routine errors rather than a lack of pharmacological effect.
- Taking an extra dose after a missed tablet.
- Stopping Azilect abruptly when symptoms improve.
- Starting an antidepressant, opioid, or cough medicine without interaction screening.
- Failing to report hallucinations, sudden sleep, or impulse-control changes.
- Assuming dizziness is unavoidable and continuing to walk without support.
- Changing levodopa timing while trying to assess rasagiline.
- Treating new dyskinesia by skipping medicines without clinical advice.
- Forgetting to mention herbal products, especially St John’s wort.
One useful observation is to record the time of each tablet, levodopa doses, meals, sleep, falls, and periods of stiffness. This can reveal whether symptoms follow a medicine schedule or another daily trigger.
Do not crush or split an oral tablet unless the product information and prescriber allow it. Altering a tablet can make administration unreliable.
What doctors say
Neurologists usually judge Azilect by practical function rather than by one isolated symptom. Walking distance, turning in bed, getting dressed, handwriting, freezing episodes, and the ability to rise from a chair can provide more useful information than a general impression of feeling better. The review also considers how symptoms affect work, exercise, and daily routines. Family observations can clarify changes that the patient may not notice. Blood pressure and alertness are assessed alongside motor function. Follow-up findings help determine whether the regimen needs adjustment.
A common clinical mistake is expecting a rapid change after the first tablet. Rasagiline supports dopamine signalling gradually within an established treatment plan, while Parkinson’s symptoms also fluctuate with sleep, meals, stress, infection, and other medicines.
The EMA product information supports monotherapy and adjunct use with levodopa, while clinical guidance places medication choice within a broader plan that includes physiotherapy, exercise, falls prevention, and review of non-motor symptoms [3].
Physicians also assess cognition, hallucinations, blood pressure, constipation, urinary symptoms, mood, and sleep. A treatment that improves stiffness but causes dangerous daytime sleepiness may need adjustment.
Frequently asked questions
Is Azilect used for Parkinson’s disease?
Yes. Azilect is indicated for adult Parkinson’s disease as monotherapy or alongside levodopa, according to the EMA product information published in 2015. It helps support dopamine signalling by inhibiting MAO-B. The degree of benefit depends on remaining dopamine pathways and the wider treatment plan.
How does rasagiline work?
Rasagiline is a selective, irreversible MAO-B inhibitor. The WHO ATC classification places it under dopaminergic anti-Parkinson medicines, reflecting its action on dopamine metabolism. The WHO index entry was published in 2024. By reducing dopamine breakdown, it can support movement control without directly converting into dopamine.
Can Azilect be taken with levodopa?
Azilect can be prescribed with levodopa in suitable adults with Parkinson’s disease. The EMA describes this adjunct approach, while clinical monitoring focuses on dyskinesia, hallucinations, low blood pressure, and sleepiness. The EMA product information dates from 2015. A change in levodopa symptoms does not automatically mean that the rasagiline dose should be changed.
Can Azilect be combined with antidepressants?
Some antidepressant combinations may be possible, while others are contraindicated or require careful washout periods. NICE guidance on Parkinson’s disease and medicines management supports reviewing the complete medication list before adding treatment [4]. The NICE guideline was published in 2017. Fluoxetine, fluvoxamine, opioids, dextromethorphan, and other MAO inhibitors require specific interaction assessment.
Does Azilect stop Parkinson’s disease from progressing?
No. Rasagiline is used for symptom management and does not restore lost dopamine-producing nerve cells. The Cochrane evidence review of rasagiline examined symptomatic and treatment outcomes but does not support describing it as a cure. The Cochrane review was published in 2015. Exercise, physiotherapy, falls prevention, and review of non-motor symptoms remain important parts of care.
What should happen after a missed dose?
Take the next scheduled dose at the usual time and do not double the amount. The EMA product information supports regular once-daily administration rather than compensatory dosing. The EMA product information was published in 2015. Repeated missed doses should be discussed during the next treatment review because irregular use makes symptom assessment more difficult.
Can Azilect cause sleepiness or hallucinations?
Yes. Sleepiness, sudden sleep episodes, hallucinations, and confusion can occur, especially when rasagiline is combined with other dopaminergic medicines. The EMA and Parkinson’s disease clinical guidance identify these effects as reasons for prompt treatment review. The EMA information was published in 2015. Avoid driving or hazardous activities if unexpected sleep or impaired alertness develops.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Azilect: Reviews and Experiences
3.6
Based on 4 reviews
Verified
My morning stiffness improved, but I noticed more involuntary finger movements after levodopa. The neurologist adjusted the wider regimen rather than increasing Azilect. That reduced the movements without losing the walking benefit.
14 Oct 2026
Verified
I developed dizziness when standing and had two near-falls during the first weeks. Taking more care when rising helped, but the treatment still needed review. The medicine was not a quick fix.
21 Oct 2026
Verified
Walking became smoother over several weeks. Later, my family noticed that I was unusually sleepy in the afternoon, which I had not recognised myself. The neurologist changed the timing of treatment.
1 Nov 2026
Sources
- European Medicines Agency (EMA) (2015). Azilect: EPAR — Product Information.
- Cochrane (2015). Rasagiline for Parkinson’s disease.
- European Medicines Agency (EMA) (2015). Azilect: European public assessment report.
- National Institute for Health and Care Excellence (NICE) (2017). Parkinson’s disease in adults: diagnosis and management, NG71.
